Skip to main content

Table 2 Univariate and multivariate analysis of associated with fatty change in Normal-GGT and Abnormal-GGT group

From: Frequently abnormal serum gamma-glutamyl transferase activity is associated with future development of fatty liver: a retrospective cohort study

Factors

Normal-GGT

  

Abnormal-GGT

  

Univariate analysis

Non-fatty change

Fatty change

Pvalue

HR (95% CI)

Non-fatty change

Fatty change

Pvalue

HR (95%CI)

Total number, n

2635

78

  

251

13

  

Gender, male/female

947/1688

35/43

0.11

1.44 (0.92–2.25)

67/184

7/6

0.13

0.43 (0.15–1.29)

Age, years

54.6 (11.8)

52.5 (10.7)

0.11

0.99 (0.97–1.00)

55.3 (10.2)

52.1 (9.5)

0.28

0.97 (0.92–1.02)

Heart disease

131 (5.0%)

5 (6.4%)

0.55

1.32 (0.53–3.26)

18 (7.2%)

2 (15.4%)

0.29

2.27 (0.50–10.23)

Hyper tension

532 (20.2%)

22 (28.2%)

0.09

1.54 (0.94–2.53)

63 (25.1%)

5 (38.5%)

0.28

1.86 (0.61–5.68)

Hyperlipidemia

533 (20.2%)

20 (25.6%)

0.25

1.35 (0.81–2.25)

50 (19.9%)

3 (23.1%)

0.76

1.22 (0.34–4.44)

Hyperuricemia

67 (2.5%)

3 (3.8%)

0.47

1.53 (0.48–4.86)

15 (6.0%)

0 (0.7%)

0.56

0.05 (0.0–1336.60)

Diabetes

87 (3.3%)

5 (6.4%)

0.14

1.98 (0.80–4.90)

12 (4.8%)

0 (0.0%)

0.60

0.05 (0.00–4392.93)

BMI

21.0 (2.5)

23.4 (2.5)

< 0.01

1.29 (1.22–1.37)

22.0 (2.5)

22.5 (1.7)

0.48

1.08 (0.87–1.36)

Hemoglobin g/dl

13.1 (1.3)

13.5 (1.2)

< 0.01

1.31 (1.09–1.58)

13.8 (1.2)

13.6 (1.4)

0.52

0.86 (0.55–1.35)

Platelet count, 104/μl

22.2 (5.3)

23.1 (4.9)

0.15

1.03 (0.99–1.07)

22.4 (5.7)

26.4 (6.0)

0.01

1.07 (1.014–1.125)

ALT, IU/l

16.6 (7.5)

20.0 (10.4)

< 0.01

1.03 (1.01–1.04)

24.5 (14.9)

20.5 (7.4)

0.31

0.97 (0.91–1.03)

Albumin, g/dl

4.2 (0.24)

4.3 (0.20)

< 0.01

4.28 (1.68–10.86)

4.3 (0.23)

4.4 (0.25)

0.14

6.58 (0.55–78.44)

Total cholesterol, mg/dl

208.1 (32.7)

207.9 (29.7)

0.91

1.00 (0.99–1.01)

205.4 (31.5)

222.9 (30.6)

0.06

1.02 (1.00–1.03)

Triglyceride, mg/dl

82.5 (40.0)

103.4 (49.2)

< 0.01

1.01 (1.00–1.01)

96.1 (43.8)

146.7 (94.9)

< 0.01

1.01 (1.00–1.02)

LDL, mg/dl

123.2 (27.8)

126.2 (24.0)

0.37

1.00 (1.00–1.01)

120.9 (27.7)

130.5 (31.7)

0.23

1.01 (0.99–1.03)

HDL, mg/dl

68.3 (16.0)

60.9 (16.3)

< 0.01

0.97 (0.95–0.98)

65.3 (15.9)

63.0 (13.8)

0.63

0.99 (0.96–1.03)

eGFR mL/min/1.73 m2

68.5 (12.5)

69.4 (9.1)

0.52

1.01 (0.99–1.02)

66.9 (12.5)

71.2 (12.3)

0.22

1.03 (0.98–1.07)

FBS, mg/dl

98.3 (13.3)

103.5 (13.2)

< 0.01

1.01 (1.01–1.02)

102.5 (15.3)

101.3 (8.2)

0.78

0.99 (0.95–1.04)

Multivariate analysis

  

Pvalue

HR (95%CI)

  

Pvalue

HR(95%CI)

BMI

  

< 0.01

1.26 (1.19–1.34)

    

ALT, IU/l

  

0.045

1.02 (1.00–1.04)

    

Albumin, g/dl

  

< 0.01

5.79 (2.20–15.26)

    

Triglyceride, mg/dl

  

0.03

1.00 (1.00–1.01)

  

< 0.01

1.01(1.00–1.02)

  1. Data are presented as numbers with SD or percentages in parentheses
  2. HR Hazard ratio, CI Confidence interval, Normal-GGT Normal-GGT, normal serum gamma-glutamyltransferase values detected during the observation period, Abnormal-GGT Elevated serum gamma-glutamyltransferase values detected more than half the times during observation period, BMI Body mass index, ALT Alanine aminotransferase, LDL Low-density lipoprotein, HDL High-density lipoprotein, eGFR Estimated glomerular filtration rate, FBS Fasting blood sugar